ATE203913T1 - Eine gelpräparation aus vernetzter gelatine, die einen basischen wachstumsfaktor für fibroblasten enthält - Google Patents

Eine gelpräparation aus vernetzter gelatine, die einen basischen wachstumsfaktor für fibroblasten enthält

Info

Publication number
ATE203913T1
ATE203913T1 AT94916430T AT94916430T ATE203913T1 AT E203913 T1 ATE203913 T1 AT E203913T1 AT 94916430 T AT94916430 T AT 94916430T AT 94916430 T AT94916430 T AT 94916430T AT E203913 T1 ATE203913 T1 AT E203913T1
Authority
AT
Austria
Prior art keywords
cross
growth factor
linked gelatin
fibroblasts
gel preparation
Prior art date
Application number
AT94916430T
Other languages
English (en)
Inventor
Yoshito Ikada
Yasuhiko Tabata
Shigeki Hijikata
Makoto Tamura
Original Assignee
Kaken Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharma Co Ltd filed Critical Kaken Pharma Co Ltd
Application granted granted Critical
Publication of ATE203913T1 publication Critical patent/ATE203913T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT94916430T 1993-05-31 1994-05-31 Eine gelpräparation aus vernetzter gelatine, die einen basischen wachstumsfaktor für fibroblasten enthält ATE203913T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP15274993 1993-05-31
PCT/JP1994/000876 WO1994027630A1 (en) 1993-05-31 1994-05-31 Cross-linked gelatin gel preparation containing basic fibroblast growth factor

Publications (1)

Publication Number Publication Date
ATE203913T1 true ATE203913T1 (de) 2001-08-15

Family

ID=15547330

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94916430T ATE203913T1 (de) 1993-05-31 1994-05-31 Eine gelpräparation aus vernetzter gelatine, die einen basischen wachstumsfaktor für fibroblasten enthält

Country Status (6)

Country Link
US (1) US6831058B1 (de)
EP (1) EP0702959B1 (de)
JP (1) JP3639593B2 (de)
AT (1) ATE203913T1 (de)
DE (1) DE69427908T2 (de)
WO (1) WO1994027630A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011046749A (ja) * 1996-08-27 2011-03-10 Baxter Internatl Inc 癒着防止用の断片化重合体ヒドロゲルおよびそれらの調製
US7435425B2 (en) 2001-07-17 2008-10-14 Baxter International, Inc. Dry hemostatic compositions and methods for their preparation
US8303981B2 (en) 1996-08-27 2012-11-06 Baxter International Inc. Fragmented polymeric compositions and methods for their use
US8603511B2 (en) 1996-08-27 2013-12-10 Baxter International, Inc. Fragmented polymeric compositions and methods for their use
US6066325A (en) 1996-08-27 2000-05-23 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
US6063061A (en) * 1996-08-27 2000-05-16 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
AU736784B2 (en) * 1997-06-03 2001-08-02 Celltran Limited New medicaments based on polymers composed of methacrylamide-modified gelatin
CN1180841C (zh) * 1999-09-30 2004-12-22 科研制药株式会社 胸骨切开术后促进胸骨愈合的方法
AU7957800A (en) * 1999-10-26 2001-05-08 Kaken Pharmaceutical Co., Ltd. Vessel embolic material comprising hydrogel and therapy with the use thereof
WO2002019887A2 (en) * 2000-09-05 2002-03-14 Technion Research And Development Foundation Ltd. Methods of repairing longitudinal bone defects
JP2003238439A (ja) * 2002-02-13 2003-08-27 Yasuhiko Tabata 虚血治療剤
CA2481214A1 (en) * 2002-04-01 2003-10-09 Kaken Pharmaceutical Co., Ltd. Viscous preparation for dental use containing basic fibroblast growth factor
JP2004115413A (ja) * 2002-09-25 2004-04-15 Yasuhiko Tabata 冠状動脈狭窄または閉塞治療用徐放性製剤
JP2004123576A (ja) * 2002-09-30 2004-04-22 Medgel Corp 多血小板血漿を含有する徐放性製剤
US8834864B2 (en) 2003-06-05 2014-09-16 Baxter International Inc. Methods for repairing and regenerating human dura mater
JP4578067B2 (ja) * 2003-06-06 2010-11-10 宏 清水 局所医薬組成物
WO2004113335A2 (en) * 2003-06-20 2004-12-29 Chiron Corporation Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents
US7927626B2 (en) 2003-08-07 2011-04-19 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
JP4532092B2 (ja) * 2003-09-30 2010-08-25 泰彦 田畑 血管新生剤
WO2005037144A2 (en) * 2003-10-10 2005-04-28 Cellular Bioengineering, Inc. Methods and compositions for growing corneal endothelial and related cells on biopolymers and creation of artifical corneal transplants
JP2005218780A (ja) * 2004-02-09 2005-08-18 Menicon Co Ltd 薬物放出速度を制御し得る薬物徐放可能なヒドロゲル材料の製造方法
WO2005087257A1 (ja) * 2004-03-16 2005-09-22 Kaken Pharmaceutical Co., Ltd. 架橋ゼラチンゲルを担体とする軟骨組織修復治療剤
WO2005097166A1 (ja) * 2004-04-09 2005-10-20 Kaken Pharmaceutical Co., Ltd. ゼラチンゲルを担体とする糖尿病性神経障害治療剤
JP2005325075A (ja) * 2004-05-14 2005-11-24 Yasuhiko Tabata 架橋ゼラチンゲルを担体とする半月板損傷治療剤
EP1857494B1 (de) * 2005-02-14 2013-06-26 Medgel Corporation Hydrogel zur medizinischen verwendung
WO2007046540A1 (ja) * 2005-10-19 2007-04-26 Osaka University 象牙質－歯髄複合体再生治療剤
US20070154546A1 (en) * 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
MX2008014847A (es) 2006-05-31 2009-04-30 Baxter Int Metodo para crecimiento interno en la celula dirigido y regeneracion controlada de los tejidos en la cirugia espinal.
US20090269404A1 (en) * 2006-08-01 2009-10-29 Nichiban Co., Ltd Crosslinked Gelatin Gel, Multilayered Structure, Carrier for Bioactive Factor, Preparation for Release of Bioactive Factor, and Their Production Methods
TWI436793B (zh) 2006-08-02 2014-05-11 巴克斯特國際公司 快速作用之乾密封膠及其使用和製造方法
JPWO2008047904A1 (ja) * 2006-10-20 2010-02-25 国立大学法人名古屋大学 閉塞性末梢血管疾患治療剤、およびその利用
EP2100914B1 (de) * 2006-12-13 2019-07-24 FUJIFILM Corporation Verfahren zur herstellung von modifiziertem biopolymer und verfahren zum vernetzen von biopolymeren
JP5047603B2 (ja) * 2006-12-15 2012-10-10 エア・ウォーター株式会社 ゼラチン成形物およびその製造方法
EP1961414A1 (de) * 2007-02-21 2008-08-27 FUJIFILM Manufacturing Europe B.V. Rekombinante Gelatine enthaltende Zusammensetzung mit gesteuerter Freisetzung
EP1961411A1 (de) * 2007-02-21 2008-08-27 FUJIFILM Manufacturing Europe B.V. Zusammensetzung mit gesteuerter Freisetzung
US8349589B2 (en) * 2007-02-12 2013-01-08 Fujifilm Manufacturing Europe B.V. Non-natural recombinant gelatins with enhanced functionality
DE102007051059B4 (de) * 2007-10-18 2014-04-03 NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen Bioverbundmaterial für die kontrollierte Freisetzung von Wirkstoffen
TWI461227B (zh) 2007-10-30 2014-11-21 Baxter Int 再生生物功能性膠原生物基質用來治療內臟或體壁缺陷的用途
WO2009060608A1 (ja) 2007-11-07 2009-05-14 Ono Pharmaceutical Co., Ltd. Ｓｄｆ－１を含有してなる徐放性組成物
EP2259803B2 (de) 2008-02-29 2019-03-13 Ferrosan Medical Devices A/S Vorrichtung zur förderung von hämostase und/oder wundheilung
WO2010089873A1 (ja) * 2009-02-05 2010-08-12 ニチバン株式会社 照射架橋水溶性高分子粒子及び照射架橋ゼラチン粒子並びにこれらの製造方法
US20120101040A1 (en) * 2009-05-07 2012-04-26 Fujifilm Corporation angiogenesis inducing agent comprising recombinant gelatin
US9039783B2 (en) 2009-05-18 2015-05-26 Baxter International, Inc. Method for the improvement of mesh implant biocompatibility
ES2532428T3 (es) 2009-06-16 2015-03-26 Baxter International Inc Esponja hemostática
WO2011010399A1 (ja) * 2009-07-24 2011-01-27 千寿製薬株式会社 角膜内皮細胞増殖促進剤
WO2011052089A1 (ja) * 2009-11-02 2011-05-05 ニチバン株式会社 電離性放射線で架橋したヒドロゲルから成る生体内薬剤徐放用担体材料及びその製造方法
WO2011059112A1 (ja) * 2009-11-13 2011-05-19 株式会社日立ハイテクノロジーズ 粒子含有細胞集合体
MX2012007056A (es) 2009-12-16 2012-09-28 Baxter Healthcare Sa Esponja hemostatica.
SA111320355B1 (ar) 2010-04-07 2015-01-08 Baxter Heathcare S A إسفنجة لايقاف النزف
WO2011151386A1 (en) 2010-06-01 2011-12-08 Baxter International Inc. Process for making dry and stable hemostatic compositions
EP2575775B1 (de) 2010-06-01 2018-04-04 Baxter International Inc. Verfahren zur herstellung von trockenen und stabilen hämostatischen zusammensetzungen
JP6289096B2 (ja) 2010-06-01 2018-03-07 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 乾燥した安定な止血組成物を作製するためのプロセス
AU2012318258B2 (en) 2011-10-11 2015-07-09 Baxter Healthcare S.A. Hemostatic compositions
EP4137165A1 (de) 2011-10-11 2023-02-22 Baxter International Inc. Hämostatische zusammensetzungen
WO2013060770A1 (en) 2011-10-27 2013-05-02 Baxter International Inc. Hemostatic compositions
RU2657955C2 (ru) 2012-03-06 2018-06-18 Ферросан Медикал Дивайсиз А/С Контейнер под давлением, содержащий гемостатическую пасту
RU2636240C2 (ru) 2012-06-12 2017-11-21 Ферросан Медикал Дивайсиз А/С Сухая гемостатическая композиция
US9347037B2 (en) * 2013-02-11 2016-05-24 Evan Masataka Masutani Methods and apparatus for building complex 3D scaffolds and biomimetic scaffolds built therefrom
WO2014126222A1 (ja) * 2013-02-15 2014-08-21 国立大学法人高知大学 ハイドロゲルを担体として過酸化水素を徐放する腫瘍内局注用の放射線/化学療法増感剤
CN105358071B (zh) 2013-06-21 2018-07-31 弗罗桑医疗设备公司 真空膨胀的干组合物和用于保留该干组合物的注射器
WO2015086028A1 (en) 2013-12-11 2015-06-18 Ferrosan Medical Devices A/S Dry composition comprising an extrusion enhancer
US11046818B2 (en) 2014-10-13 2021-06-29 Ferrosan Medical Devices A/S Dry composition for use in haemostasis and wound healing
CN107206165B (zh) 2014-12-24 2020-10-23 弗罗桑医疗设备公司 用于保持并混合第一和第二物质的注射器
CA2986981A1 (en) 2015-07-03 2017-01-12 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
JP6646689B2 (ja) * 2016-01-25 2020-02-14 サントリーホールディングス株式会社 機能性物質を含有するカプセル及びその製造方法
WO2017170487A1 (ja) * 2016-03-28 2017-10-05 富士フイルム株式会社 製剤、製剤用部材およびそれらの製造方法
EP3790600B1 (de) 2018-05-09 2023-12-27 Ferrosan Medical Devices A/S Verfahren zur herstellung einer hämostatischen zusammensetzung
JP2023015416A (ja) * 2019-12-27 2023-02-01 Ｅａファーマ株式会社 瘻孔治療用材料

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3923969A (en) * 1973-06-12 1975-12-02 Battelle Institut E V Carrier system for a drug with sustained release
US4785079A (en) * 1984-11-09 1988-11-15 The Salk Institute For Biological Studies Isolation of fibroblast growth factor
MX163953B (es) * 1984-03-27 1992-07-03 Univ New Jersey Med Procedimiento para preparar una matriz biodegradable a base de colageno
JPH0759522B2 (ja) * 1985-12-27 1995-06-28 住友製薬株式会社 徐放性製剤の製造法
JP2587219B2 (ja) * 1986-06-10 1997-03-05 エーザイ株式会社 溶解遅延性のゼラチン製剤組成物
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
US5164410A (en) * 1988-01-09 1992-11-17 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
JPH01282394A (ja) 1988-05-10 1989-11-14 Toshiba Corp 電動機の張力制御装置
US4950483A (en) * 1988-06-30 1990-08-21 Collagen Corporation Collagen wound healing matrices and process for their production
JPH0249734A (ja) * 1988-08-12 1990-02-20 Wakunaga Pharmaceut Co Ltd 新規組成物
US5202311A (en) * 1988-08-19 1993-04-13 Children's Medical Center Corporation Stabilized fgf composition
US5298243A (en) * 1988-10-20 1994-03-29 Denki Kagaku Kogyo Kabushiki Kaisha Colony stimulating factor-gelatin conjugate
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
CA2020654A1 (en) * 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
GB9014871D0 (en) * 1990-07-05 1990-08-22 Erba Carlo Spa Drug delivery system for administering growth factor
JP3135138B2 (ja) * 1990-12-19 2001-02-13 科研製薬株式会社 骨疾患治療剤
JPH05132426A (ja) * 1991-02-15 1993-05-28 Takeda Chem Ind Ltd 骨組織の形成促進剤
US5270300A (en) * 1991-09-06 1993-12-14 Robert Francis Shaw Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone
WO1995024211A1 (en) * 1994-03-08 1995-09-14 Osteosa, Inc. Use of fibroblast growth factors to stimulate bone growth
US5656598A (en) * 1994-03-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Use of fibroblast growth factors to stimulate bone growth

Also Published As

Publication number Publication date
WO1994027630A1 (en) 1994-12-08
JP3639593B2 (ja) 2005-04-20
EP0702959B1 (de) 2001-08-08
EP0702959A4 (de) 1996-11-27
US6831058B1 (en) 2004-12-14
DE69427908T2 (de) 2001-11-22
EP0702959A1 (de) 1996-03-27
DE69427908D1 (de) 2001-09-13

Similar Documents

Publication Publication Date Title
ATE203913T1 (de) Eine gelpräparation aus vernetzter gelatine, die einen basischen wachstumsfaktor für fibroblasten enthält
DE69414626D1 (de) Helle Haarpflegezusammensetzung
CA2047154A1 (en) Hair dye composition and its application method
DE3855388D1 (de) 7-Piperazinyl- oder 7-Morpholino-4-oxo-Chinolin-3- carbonsäurederivate, ihre Herstellung und ihre Verwendung als antimikrobielle Mittel
ES2164691T3 (es) Formulacion de insulina.
DE3780329D1 (de) Chinoloncarbonsaeure-derivate und ihre herstellung.
SE8603228D0 (sv) Sarlekningsmedel
FI905003A0 (fi) Glykosaminoglykan modifierat protein.
DE3788840D1 (de) Wasserabsorbierende Zusammensetzung mit verlängerter Lagerfähigkeit und welche die Faserbildung erleichtert.
CA2006386A1 (en) Absorbent material
DE3768598D1 (de) Neue retinoide, deren herstellung und verwendung als pharmazeutika.
IT8721063A0 (it) Composizione ad attivita'tricogena.
DE68905705D1 (de) Sphaerische phosphoraggregate, ihre herstellung und verwendung in roentgenstrahlschirmen.
ATE90510T1 (de) Antimikrobische zusammensetzung und deren verwendung.
PT86153A (de) Optisch aktive gyrasehemmer ihre herstellung und verwendung als antibiotika
NO902104D0 (no) Kosmetisk blanding.
ATE45164T1 (de) Steroido(3,2-c>-pyrazole, als antiandrogene und ihre herstellung.
ITRM920384A1 (it) Procedimento per la produzione di leuco coloranti allo zolfo e prodotto ottenuto.
EP0409369A3 (en) Substituted pyrimidinyloxy-(thio)-and triazinyloxy-(thio)acrylic acid derivatives, process for their preparation and their use as an agent with herbicidic, fungicidic and plantgrowth regulating activity
DE3862766D1 (de) Reaktivfarbstoffe, deren herstellung und verwendung.
DE3868287D1 (de) Reaktivfarbstoffe, deren herstellung und verwendung.
DE68912083D1 (de) Substituierte Karbonsäuren, ihre Herstellung und Verwendung.
DE3868104D1 (de) Reaktivfarbstoffe, deren herstellung und verwendung.
DE3872161D1 (de) Reaktivfarbstoffe, deren herstellung und verwendung.
DK181089D0 (da) 1-dimethylcarbamoyl-3-substituerede-5-substituerede-1h-1,2,4-triazoler

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties